PATIENT ENROLLMENT IN A PHASE IB STUDY COMPLETED AHEAD OF SCHEDULE

This is a multicenter, double-blind, randomized phase Ib study that aims to evaluate the therapy’s impact in subjects with moderately and severely active ulcerative colitis.
 
Patient enrollment has been completed 5 months earlier than initially planned. At the same time, screen failure rate (SFR) turned out to be 5% lower than expected. The study is being conducted in Georgia, Moldova and Ukraine. Participants include men and women between the ages of 18 and 75. The total duration of therapy is 12 weeks.

Within this project, OCT team is responsible for the following activities: project management, clinical and medical monitoring, quality control and logistics.
Back to the list